PDMR Dealing
LONDON, March 20, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 18, 2019, Mr. Piers Morgan, CFO of the Company, purchased 34,481 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 58 pence per Ordinary Share and a total purchase price of £19,999.98 Following the acquisition, Mr. Morgan will have an interest in the Company of 93,075 Ordinary Shares, representing 0.09% of the Company’s issued share capital.
The purchase by Mr. Morgan follows the purchases made by the Company’s Chairman, Dr. David Ebsworth, earlier this month totaling approximately £50,000.00.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Piers Morgan |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Financial Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Verona Pharma plc |
| b) | LEI |
213800EVI6O6J3TIAL06 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of 5 pence each GB00BYW2KH80 |
|
| b) | Nature of the transaction |
Piers Morgan purchased Ordinary Shares | |
| c) | Price(s) and volume(s) |
Price(s) | Volume(s) |
| 58 pence per Ordinary Share | 34,481 Ordinary Shares | ||
| d) | Aggregated information - Aggregated volume - Price |
N/A | |
| e) | Date of the transaction | 18 March 2019 | |
| f) | Place of the transaction | London Stock Exchange, AIM | |
For further information, please contact:
| Verona Pharma plc | Tel: +44 (0)20 3283 4200 |
| Jan-Anders Karlsson, Chief Executive Officer Victoria Stewart, Director of Communications |
info@veronapharma.com |
| Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker) |
Tel: +44 (0) 20 7710 7600 |
| Stewart Wallace / Jonathan Senior / Ben Maddison |